Tevogen Bio Holdings Inc. announced that its AI arm, Tevogen.AI, is close to completing the training of its PredicTcell™ machine‑learning model and has launched an internal application portal to host the model in a scalable, user‑friendly environment. The milestone marks a tangible step toward commercial readiness for the AI platform and lays the groundwork for potential future customer‑facing services.
The PredicTcell™ model was trained on one of the industry’s largest curated peptide datasets and now incorporates more than 180 parameters, an expansion from the 27 features highlighted in a September 2025 update. The model’s precision has improved by roughly 10%, a gain that the company attributes to the larger dataset and refined feature set. This improvement is expected to accelerate target identification for Tevogen’s ExacTcell™ platform, which develops off‑the‑shelf, precision T‑cell therapies for oncology, neurology, and virology.
Tevogen.AI’s progress is part of a broader strategy to integrate AI into the drug‑development pipeline. The company partners with Microsoft and Databricks for cloud and data services, and the internal portal will enable rapid iteration and testing of the model across the organization. By making the AI tool available internally, Tevogen aims to reduce development timelines and costs, thereby increasing the speed at which new therapies can reach patients.
Chief Information Officer and Head of Tevogen.AI, Mittul Mehta, said, “Advancing PredicTcell toward completion marks an important milestone in our AI strategy. As we begin exploring commercial pathways, our focus remains on maintaining scientific rigor while building scalable tools that can extend the impact of our platform beyond internal use.”
While the AI milestone is a positive development, Tevogen Bio has recently been notified by Nasdaq that it no longer meets the minimum market‑value listing standards and has until October 2026 to regain compliance. The company’s continued investment in AI and the potential for new revenue streams may help address this headwind, but the Nasdaq compliance issue remains a significant risk factor for investors.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.